company background image
EBS

Emergent BioSolutions NYSE:EBS Stock Report

Last Price

US$13.47

Market Cap

US$672.0m

7D

-0.4%

1Y

-71.2%

Updated

30 Jan, 2023

Data

Company Financials +

Emergent BioSolutions Inc.

NYSE:EBS Stock Report

Mkt Cap: US$672.0m

EBS Stock Overview

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States.

EBS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance1/6
Financial Health2/6
Dividends0/6

My Notes

New

Notes are coming soon

Emergent BioSolutions Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Emergent BioSolutions
Historical stock prices
Current Share PriceUS$13.47
52 Week HighUS$47.71
52 Week LowUS$10.61
Beta0.89
1 Month Change14.06%
3 Month Change-35.61%
1 Year Change-71.22%
3 Year Change-76.30%
5 Year Change-70.49%
Change since IPO15.13%

Recent News & Updates

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Recent updates

A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)

Aug 13
A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt

Jul 26
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt

Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate

May 12
Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate

Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet

Apr 24
Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet

Are Investors Undervaluing Emergent BioSolutions Inc. (NYSE:EBS) By 39%?

Feb 08
Are Investors Undervaluing Emergent BioSolutions Inc. (NYSE:EBS) By 39%?

Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?

Jan 20
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?

Is There An Opportunity With Emergent BioSolutions Inc.'s (NYSE:EBS) 43% Undervaluation?

Nov 08
Is There An Opportunity With Emergent BioSolutions Inc.'s (NYSE:EBS) 43% Undervaluation?

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Oct 21
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Is Emergent BioSolutions (NYSE:EBS) A Risky Investment?

Jul 23
Is Emergent BioSolutions (NYSE:EBS) A Risky Investment?

Here's Why I Think Emergent BioSolutions (NYSE:EBS) Might Deserve Your Attention Today

Jul 06
Here's Why I Think Emergent BioSolutions (NYSE:EBS) Might Deserve Your Attention Today

Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?

Apr 18
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?

Is Now The Time To Put Emergent BioSolutions (NYSE:EBS) On Your Watchlist?

Mar 31
Is Now The Time To Put Emergent BioSolutions (NYSE:EBS) On Your Watchlist?

The Independent Director of Emergent BioSolutions Inc. (NYSE:EBS), Sue Bailey, Just Sold 34% Of Their Holding

Mar 13
The Independent Director of Emergent BioSolutions Inc. (NYSE:EBS), Sue Bailey, Just Sold 34% Of Their Holding

The Emergent BioSolutions (NYSE:EBS) Share Price Is Up 187% And Shareholders Are Boasting About It

Mar 02
The Emergent BioSolutions (NYSE:EBS) Share Price Is Up 187% And Shareholders Are Boasting About It

Shareholder Returns

EBSUS BiotechsUS Market
7D-0.4%0.8%2.8%
1Y-71.2%7.1%-9.2%

Return vs Industry: EBS underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: EBS underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is EBS's price volatile compared to industry and market?
EBS volatility
EBS Average Weekly Movement13.7%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: EBS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: EBS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19982,416Bob Kramerhttps://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company’s products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate.

Emergent BioSolutions Inc. Fundamentals Summary

How do Emergent BioSolutions's earnings and revenue compare to its market cap?
EBS fundamental statistics
Market CapUS$671.99m
Earnings (TTM)US$53.50m
Revenue (TTM)US$1.51b

12.6x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EBS income statement (TTM)
RevenueUS$1.51b
Cost of RevenueUS$902.90m
Gross ProfitUS$610.50m
Other ExpensesUS$557.00m
EarningsUS$53.50m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.07
Gross Margin40.34%
Net Profit Margin3.54%
Debt/Equity Ratio72.7%

How did EBS perform over the long term?

See historical performance and comparison